Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619314 | 1.00 | KCNH2 (0.72) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4128937 | 0.94 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4134400 | 0.94 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4134172 | 0.93 | KCNH2 (0.66) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1619266 | 0.89 | KCNH2 (0.58) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7031260 | 0.89 | KCNH2 (0.58) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5374500 | 0.89 | KCNH2 (0.70) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4130161 | 0.88 | KCNH2 (0.56) | KCNH2KDM4EMAPK1POLBL3MBTL1 | |
| SCHEMBL4142281 | 0.88 | KCNH2 (0.56) | KCNH2KDM4EKMT2AMAPK1POLB | |
| SCHEMBL4128190 | 0.88 | KCNH2 (0.59) | KCNH2KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915380-A1 | PROCESS FOR THE PREPARATION OF N,N´- DISUBSTITUTED OXABISPIDINES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2006137770-A1 | PROCESS FOR THE PREPARATION OF N,N´- DISUBSTITUTED OXABISPIDINES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | claimed |
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ASTRAZENECA AB (SE) | 2010-09-02 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| CN-1279916-C | 3,7-diazybicyclo [3.3.1] for mulations as antiarrhytmic compounds | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | CN | disclosed |
| CN-1269823-C | 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| CN-1514837-A | 3,7-diazabicyclo [3.3.1] for mulations as anti arhythmiccompounds | — | 2004-07-21 | — | — | CN | disclosed |
| CN-1514838-A | 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds | — | 2004-07-21 | — | — | CN | disclosed |
| CN-1514839-A | 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds | — | 2004-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ADH1C, ADH5, ADH1A | KCNH2 437/4885KDM4E 3937/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.